profile background people market opportunity collaborations


WYETH: Neurome and Wyeth are working together in this collaboration to investigate a number of aspects of CNS disease, beginning with the comprehensive evaluation and morphological analysis of one of Wyeth’s transgenic animal models of Alzheimer’s disease used to evaluate selected preclinical compounds. Employing its proprietary technologies and expertise in quantitative neuropathology, Neurome will assist Wyeth in its Discovery Research efforts involving treatment of Central Nervous System (CNS) disorders. Neurome’s extensive experience with animal models of CNS diseases and proprietary technologies will allow it to derive quantitative 3-D information, including volumetric analysis, on these animals. Under the terms of the multi-year agreement, Neurome receives research funding from Wyeth.

La Jolla Pharmaceutical Company: The collaboration is focused on the investigation of proteins in the brain that selectively bind antibodies to double-stranded DNA found in patients with systemic lupus erythematosus (lupus). In combination with La Jolla Pharmaceutical Company’s experience in discovering and developing innovative therapeutics to treat the underlying causes of antibody-mediated diseases, the Neurome Technologies will be used to provide La Jolla Pharmaceutical with information on potential targets in the Central Nervous System (CNS) affected by lupus.

Elan Corporation, plc.: The research partnership with Elan has an initial term of 3 years and may generate up to $4 million in service revenue for Neurome, together with shared ownership of the diagnostic and therapeutic applications of the genes, circuits and mechanisms identified in the research. The partnership will utilize Neurome's technologies to analyze a mouse model of Alzheimer's Disease with the goal of identifying and exploiting molecules and pathways relevant to diagnosis and treatment of the disease. The partnership will analyze Elan's proprietary mouse model of amyloid deposition in an attempt to answer a variety of scientific questions regarding amyloid deposition.

ImClone Systems Incorporated: This partnership focuses on early-stage discovery investigation of preclinical antibody candidate molecules. Neurome is providing ImClone Systems with qualitative and quantitative information on the effects of selected preclinical antibody molecules on potential drug targets in the Central Nervous System whose corresponding behavioral effects suggest potential therapeutic mechanisms are at work.

Merck Research Labs: Neurome is applying its suite of proprietary technologies in ongoing collaboration with Merck to reveal new insights into to mechanisms underlying Central Nervous System disease.

PsychoGenics Inc.: Neurome has partnered with PsychoGenics Inc. to work together to develop better predictive test systems, along with specific biological markers for drug target expression patterns, that will enable pharmaceutical companies looking to screen new chemical entities for depression to obtain reliable behavioral readouts and their corresponding neurobiological, gene- or protein- expression signatures. An improved predictive test regiment will aid in the acceleration of the discovery and development of drugs to treat depression. This partnership is being carried out under a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Program.

© 2005 Neurome, All Rights Reserved | Privacy Statement | Terms of Use | Forward Looking Statements